You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 5, 2025

Details for Patent: 3,857,952


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 3,857,952
Title: CERTAIN BENZENE DERIVATIVES USEFUL IN TREATING CARDIAC DISORDERS
Abstract:Benzene derivatives of the formula: ##SPC1## Wherein R.sup.1 represents alkanoyl amino of not more than nine carbon atoms, R.sup.2 represents alkyl of one through six carbon atoms, and R.sup.3 represents alkyl of one through six carbon atoms or cycloalkyl of three through six carbon atoms, possess pharmacodynamic properties and are useful in the treatment of various cardiac disorders.
Inventor(s): Wooldridge; Kenneth Robert Harry (Brentwood, EN), Basil; Berkeley (Highwood, near Chelmsford, EN)
Assignee: May & Baker Limited (Dagenham, Essex, EN)
Application Number:05/277,607
Patent Claim Types:
see list of patent claims
Use; Composition; Compound; Delivery;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 3,857,952: A Detailed Analysis

Introduction

United States Patent 3,857,952, though an older patent, provides valuable insights into the evolution of patent law and the criteria for patent eligibility. This analysis will delve into the scope, claims, and the broader patent landscape surrounding this patent, drawing parallels with current patent practices and recent updates.

Background of the Patent

Patent 3,857,952 was granted in the early 1970s, a period when patent law was less complex and the technological landscape was vastly different from today. To understand its significance, it is crucial to consider the historical context in which it was issued.

Scope of the Patent

The scope of a patent is defined by its claims, which outline the specific invention and its boundaries. For older patents like 3,857,952, the scope might seem narrower compared to modern patents, which often involve more complex technologies.

  • Claim Structure: The claims in older patents typically follow a more straightforward structure, focusing on the core invention without the intricate details seen in contemporary patents. This simplicity reflects the less sophisticated technological environment of the time.
  • Subject Matter: The subject matter of the patent would be evaluated based on the standards of patentability at the time of its issuance. This includes novelty, non-obviousness, and utility, which are still fundamental principles today but have evolved in their application.

Claims Analysis

Analyzing the claims of an older patent like 3,857,952 involves understanding the language and the technological context in which they were written.

  • Independent and Dependent Claims: Independent claims define the invention broadly, while dependent claims narrow down the scope by adding specific limitations. In older patents, these claims might be less detailed but still crucial for defining the invention's boundaries.
  • Claim Interpretation: The interpretation of claims has become more nuanced over time, especially with the integration of recent case law and updated guidance from the USPTO. For example, the 2024 USPTO guidance update emphasizes the importance of integrating judicial exceptions into practical applications, a concept that would be applied differently to older patents[1].

Patent Eligibility Criteria

The criteria for patent eligibility have evolved significantly since the issuance of Patent 3,857,952.

  • Abstract Ideas and Judicial Exceptions: Modern patent law, as clarified by the 2024 USPTO guidance, places a strong emphasis on whether a claim integrates a judicial exception into a practical application. This was not as clearly defined in the past, leading to different standards for evaluating patent eligibility[1].
  • Recent Case Law: Recent Federal Circuit decisions and Supreme Court rulings have refined the standards for patent eligibility. For instance, the Supreme Court's decision in Mayo Collaborative Services v. Prometheus Laboratories, Inc. and Alice Corp. v. CLS Bank International have significantly impacted how abstract ideas are treated in patent claims[5].

Practical Applications and Real-World Benefits

The 2024 USPTO guidance highlights the importance of demonstrating real-world applications and practical benefits of the claimed invention.

  • Example from 2024 Guidance: In the context of AI-related inventions, the guidance provides examples like Claim 2 in Example 48, which specifies the use of separated audio components in a speech recognition system. This practical application transforms the abstract idea into a patent-eligible invention by providing a tangible benefit, such as improved accuracy in speech recognition systems[1].
  • Comparison with Older Patents: Older patents might not have been subject to the same level of scrutiny regarding practical applications. However, they still needed to demonstrate utility and a clear benefit, albeit in a less complex technological environment.

Impact of Recent USPTO Guidance

The 2024 USPTO guidance update has significant implications for innovators and patent practitioners, even when considering older patents.

  • AI-Assisted Inventions: The update clarifies that the method of invention development, including the use of AI, does not impact subject matter eligibility. This means that AI-assisted inventions are evaluated on equal footing with other technologies, provided there is significant human contribution[1].
  • Consistency and Clarity: The integration of recent case law and the provision of new examples in the guidance promote consistency and clarity in the application of patent eligibility criteria. This ensures that the evaluation process is more predictable and aligned with current legal standards.

Broader Patent Landscape

The patent landscape has evolved dramatically since the issuance of Patent 3,857,952.

  • Global Dossier and Public Search Facilities: Modern tools like the Global Dossier and the USPTO Public Search Facility provide extensive resources for searching and analyzing patents, facilitating a more comprehensive understanding of the patent landscape[4].
  • Patent Claims Research Dataset: The USPTO's Patent Claims Research Dataset offers detailed information on claims from US patents and applications, allowing for in-depth analysis of patent scope and trends[3].

Key Takeaways

  • Evolution of Patent Law: Patent law has become more complex and nuanced, with a greater emphasis on practical applications and real-world benefits.
  • Importance of Recent Guidance: The 2024 USPTO guidance update provides critical insights and tools for evaluating the patent eligibility of AI-related inventions and other technologies.
  • Historical Context: Understanding older patents like 3,857,952 requires considering the historical context in which they were issued and the technological environment of the time.
  • Consistency and Clarity: The integration of recent case law and new examples in the guidance ensures consistency and clarity in the application of patent eligibility criteria.

FAQs

Q: How has the criteria for patent eligibility changed since the issuance of Patent 3,857,952? A: The criteria have become more nuanced, with a greater emphasis on integrating judicial exceptions into practical applications and demonstrating real-world benefits.

Q: What is the significance of the 2024 USPTO guidance update on AI patent eligibility? A: The update clarifies the process for determining the patent eligibility of AI-related inventions, providing examples and integrating recent case law to ensure consistency and clarity.

Q: How do modern tools like the Global Dossier impact patent research and analysis? A: These tools provide extensive resources for searching and analyzing patents, facilitating a more comprehensive understanding of the patent landscape.

Q: What role does AI play in the development and evaluation of patentable inventions according to the 2024 USPTO guidance? A: AI-assisted inventions are evaluated on equal footing with other technologies, provided there is significant human contribution, and the method of invention development does not impact subject matter eligibility.

Q: How can the Patent Claims Research Dataset be used in analyzing patent scope and trends? A: The dataset provides detailed information on claims from US patents and applications, allowing for in-depth analysis of patent scope and trends.

Sources

  1. Understanding the 2024 USPTO Guidance Update on AI Patent - Mintz
  2. U.S. Patent and Trademark Office (USPTO) | USAGov
  3. Patent Claims Research Dataset - USPTO
  4. Search for patents - USPTO
  5. Berkheimer v. HP Inc. - Court of Appeals for the Federal Circuit

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 3,857,952

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Patented / Exclusive UseSubmissiondate
No data available in table
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Patented / Exclusive Use>Submissiondate
Showing 0 to 0 of 0 entries

Foreign Priority and PCT Information for Patent: 3,857,952

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom58516/67Dec 22, 1967
United Kingdom56513/68May 14, 1968
United Kingdom37103/68Aug 2, 1968

International Family Members for US Patent 3,857,952

CountryPatent NumberEstimated ExpirationSupplementary Protection CertificateSPC CountrySPC Expiration
Austria 286262 ⤷  Try for Free
Austria 286963 ⤷  Try for Free
Austria 289826 ⤷  Try for Free
>Country>Patent Number>Estimated Expiration>Supplementary Protection Certificate>SPC Country>SPC Expiration
Showing 1 to 3 of 3 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.